MerryLife Biomedical Advances TML-6 to Phase 2 Following Positive Safety Results in Alzheimer's Disease Trial
核心洞察
MerryLife Biomedical (搜索) announced positive Phase 1 results for TML-6, demonstrating the oral multi-targeted therapy was generally well tolerated with a favorable safety profile in Alzheimer's disease patients.
The company plans to initiate a global Phase 2 program enrolling approximately 210 participants with mild cognitive impairment and mild dementia across the United States, Sweden, and Taiwan.
TML-6 is designed as a first-in-class therapy that modulates autolysosomal systems and interconnected cellular pathways involved in protein clearance, neuroinflammation, and aging-related neuronal dysfunction.
MerryLife Biomedical (搜索) Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's disease. The study demonstrated that TML-6 was generally well tolerated with a favorable safety profile, supporting its continued clinical development into Phase 2 trials.
Multi-Targeted Approach to Neurodegeneration
TML-6 represents a first-in-class, orally administered therapy designed to modulate the autolysosomal system and interconnected cellular pathways involved in protein clearance, neuroinflammation, oxidative stress, and aging-related neuronal dysfunction. These biological processes are key factors underlying the progression of both Alzheimer's and Parkinson's diseases, with disruption of these pathways increasingly recognized as central to neurodegeneration.
"Neurodegenerative diseases such as Alzheimer's and Parkinson's arise from complex, interconnected biological processes that are difficult to address with single-target therapies," said Dr. Ih-Jen Su, Chief Executive Officer of MerryLife Biomedical (搜索). "TML-6 represents a multi-targeted approach with an oral formulation and a favorable safety profile, supporting earlier intervention and the potential to slow disease progression in areas of significant unmet medical need."
Global Phase 2 Program Design
Based on the positive Phase 1 results, MerryLife is preparing to initiate a global Phase 2 program in early Alzheimer's disease. The study will enroll individuals with mild cognitive impairment and mild dementia, targeting approximately 210 participants across three regions: the United States, Sweden, and Taiwan.
The Phase 2 program will further evaluate safety and tolerability while exploring disease-related biomarkers associated with multi-pathway modulation. This approach aims to provide insights into TML-6's mechanism of action and potential therapeutic benefits in early-stage Alzheimer's disease.
Expanding to Parkinson's Disease
In parallel with its Alzheimer's disease program, MerryLife is exploring the potential relevance of TML-6 in Parkinson's disease, where similar pathological mechanisms contribute to disease progression. The company's multi-targeted approach addresses the shared biological pathways involved in both neurodegenerative conditions.
MerryLife plans to present additional preclinical data and clinical development insights on TML-6 at the AD/PD™ 2026 International Conference in Copenhagen on March 19, 2026, providing further details on the therapy's development across multiple neurodegenerative indications.